Prime Medicine Reports Q2 Loss; Advances PM577a, PM647 Toward Clinical Development
Prime Medicine (PRME) reported a Q2 2026 net loss of $42.1M, narrower than the prior year. R&D and G&A expenses decreased. The company advanced PM577a and PM647 toward clinical trials, with FDA clearances and data expected in 2027. PM359 received RMAT designation, with a potential BLA filing in 2027. PRME has $108.8M in cash, expected to last into 2027.


